EE04951B1 - R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks - Google Patents

R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks

Info

Publication number
EE04951B1
EE04951B1 EEP200100122A EEP200100122A EE04951B1 EE 04951 B1 EE04951 B1 EE 04951B1 EE P200100122 A EEP200100122 A EE P200100122A EE P200100122 A EEP200100122 A EE P200100122A EE 04951 B1 EE04951 B1 EE 04951B1
Authority
EE
Estonia
Prior art keywords
piperidinemethanol
dimethoxyphenyl
fluorophenyl
alpha
treatment
Prior art date
Application number
EEP200100122A
Other languages
English (en)
Inventor
Mondadori Cesare
M. Sorensen Stephen
M. Hitchcock Janice
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of EE200100122A publication Critical patent/EE200100122A/et
Publication of EE04951B1 publication Critical patent/EE04951B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200100122A 1998-08-28 1999-07-29 R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks EE04951B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14313598A 1998-08-28 1998-08-28
PCT/US1999/017331 WO2000012090A1 (en) 1998-08-28 1999-07-29 THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS

Publications (2)

Publication Number Publication Date
EE200100122A EE200100122A (et) 2002-06-17
EE04951B1 true EE04951B1 (et) 2008-02-15

Family

ID=22502745

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100122A EE04951B1 (et) 1998-08-28 1999-07-29 R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks

Country Status (32)

Country Link
EP (2) EP1105132B1 (et)
JP (1) JP2002523460A (et)
KR (3) KR100735513B1 (et)
CN (1) CN1127954C (et)
AT (1) ATE249830T1 (et)
AU (1) AU764604B2 (et)
BG (2) BG65416B1 (et)
BR (1) BR9913242A (et)
CA (2) CA2629396A1 (et)
CZ (1) CZ300781B6 (et)
DE (2) DE69911436T2 (et)
DK (1) DK1105132T3 (et)
EA (1) EA003791B1 (et)
EE (1) EE04951B1 (et)
ES (1) ES2204146T3 (et)
HK (1) HK1040907B (et)
HR (2) HRP20010140A2 (et)
HU (1) HUP0202145A3 (et)
ID (1) ID29601A (et)
IL (2) IL141603A0 (et)
ME (1) MEP20308A (et)
MX (1) MXPA01002026A (et)
NO (2) NO20010984L (et)
NZ (1) NZ510083A (et)
PL (1) PL195022B1 (et)
PT (1) PT1105132E (et)
SK (1) SK284858B6 (et)
TR (1) TR200100670T2 (et)
TW (1) TWI233802B (et)
UA (1) UA74773C2 (et)
WO (1) WO2000012090A1 (et)
ZA (1) ZA200101466B (et)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099076A1 (en) * 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
ES2281666T3 (es) 2002-07-19 2007-10-01 Biovitrum Ab Novedosos derivados de piperazinil-pirazinona para el tratamiento de los desordenes relacionados con el receptor 5-ht2a.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169096A (en) 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4877798A (en) * 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
ATE102482T1 (de) * 1988-01-21 1994-03-15 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
DE69105501T2 (de) * 1990-06-01 1995-04-13 Merrell Dow Pharma (+)-alpha-(2,3 dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinmethanol.
JPH05134149A (ja) * 1991-11-08 1993-05-28 Nippondenso Co Ltd 光半導体モジユール
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
US9702597B1 (en) 2016-02-18 2017-07-11 King Fahd University Of Petroleum And Minerals System and method for preventing absorbent crystallization in a continuously operating solar-powered absorption cooling system with hybrid storage

Also Published As

Publication number Publication date
HUP0202145A3 (en) 2003-02-28
ZA200101466B (en) 2002-05-21
IL141603A (en) 2006-08-20
EP1362589A1 (en) 2003-11-19
DE69911436T2 (de) 2004-07-01
NO20010984D0 (no) 2001-02-27
CZ2001726A3 (en) 2001-06-13
HRP20010140A2 (en) 2002-02-28
KR100682799B1 (ko) 2007-02-15
HK1040907B (zh) 2004-04-02
KR20010073026A (ko) 2001-07-31
DE69941134D1 (de) 2009-08-27
CA2341891C (en) 2009-05-12
PT1105132E (pt) 2004-02-27
HK1040907A1 (en) 2002-06-28
NO20091111L (no) 2001-04-25
EE200100122A (et) 2002-06-17
NZ510083A (en) 2003-08-29
NO20010984L (no) 2001-04-25
AU764604B2 (en) 2003-08-21
CN1315861A (zh) 2001-10-03
EP1362589B1 (en) 2009-07-15
BG65416B1 (bg) 2008-07-31
SK284858B6 (sk) 2006-01-05
KR20060023197A (ko) 2006-03-13
ATE249830T1 (de) 2003-10-15
CZ300781B6 (cs) 2009-08-12
EA003791B1 (ru) 2003-10-30
ID29601A (id) 2001-09-06
BG109953A (en) 2007-12-28
AU5135999A (en) 2000-03-21
TR200100670T2 (tr) 2001-06-21
PL195022B1 (pl) 2007-08-31
MEP20308A (en) 2010-06-10
DK1105132T3 (da) 2003-11-24
HUP0202145A2 (hu) 2003-01-28
DE69911436D1 (de) 2003-10-23
IL141603A0 (en) 2002-03-10
CA2629396A1 (en) 2000-03-09
EA200100201A1 (ru) 2001-08-27
BG105289A (en) 2001-11-30
CA2341891A1 (en) 2000-03-09
KR100764532B1 (ko) 2007-10-09
WO2000012090A1 (en) 2000-03-09
ES2204146T3 (es) 2004-04-16
MXPA01002026A (es) 2003-03-27
EP1105132B1 (en) 2003-09-17
EP1105132A1 (en) 2001-06-13
SK2692001A3 (en) 2001-07-10
JP2002523460A (ja) 2002-07-30
HRP20080389A2 (en) 2008-11-30
TWI233802B (en) 2005-06-11
UA74773C2 (en) 2006-02-15
PL346342A1 (en) 2002-02-11
BR9913242A (pt) 2001-05-15
CN1127954C (zh) 2003-11-19
KR100735513B1 (ko) 2007-07-06
KR20060057029A (ko) 2006-05-25

Similar Documents

Publication Publication Date Title
ES2067937T3 (es) (+)-alfa-(2,3-dimetoxifenil)-1-(2-(4-fluorofenil)etil)-4-piperidinametanol.
DK0998287T3 (da) Anvendelse af levobupivacain
DE69800859D1 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
PT888114E (pt) Utilizacao de (+)-alfa-(2,3-dimetoxifenil)-1-¬2-(4-fluorofenil)etil|-4-piperidinometanol no tratamento de doencas depressivas e doencas bipolares
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
MY111623A (en) Neuroprotective compounds
MXPA04000775A (es) Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.
EE04951B1 (et) R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks
BR9708037A (pt) Método para o tratamento de abuso de substância
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
EA200200656A1 (ru) НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
YU15301A (sh) PRIMENA R (+)- alfa-(2,3-DIMETOKSIFENIL)-1-[2-(4-FLUOROFENIL) ETIL] -4-PIPERIDINMETANOLA ZA LECENJE POREMEĆAJA SPAVANJA

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20100729